Condition 1: Diabetes Mellitus. Condition 2: Other specified complications of cardiac and vascular prosthetic devices, implants and grafts. Diabetes Mellitus T82.8 Other specified complications of cardiac and vascular prosthetic devices, implants and grafts, I25.1 coronary (artery) desease
Conditions
Interventions
Intervention 1: Control group: this group will be undergone insulin protocol common at hospital since entering into the unit until releasing time by regular insulin subcutaneous injection in surgery u
Treatment - Drugs
Control group: this group will be undergone insulin protocol common at hospital since entering into the unit until releasing time by regular insulin subcutaneous injection in surgery unit and intensiv
Test group: this group will be undergone a revised new protocol of insulin since entering into the unit until releasing time by regular subcutaneous insulin injection in surgery unit and intensive car
Sponsors
Tehran University of Medical Sciences
Shahid Madani Cardiovascular Research Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria were; Patients who underwent elective coronary artery bypass surgery and the first time (with on pump or off pump) , who the day before surgery were be hospitalized; Patients who have type 2 diabetes diagnosed during hospitalization or admission to the hospital by blood sugar test, blood sugar after a meal and a diagnosis of type 2 diabetes after glucose tolerance ; patients who did not have other heart disease exception of coronary artery disease; patients with a creatinine level less than 2, patients who did not have kidney disease; not having another heart attack or another heart surgery at same time; no previous heart surgery; positive history of past severe disease; on-emergency surgery; non-cytotoxic drugs and radiation use.Exclusion criteria were; the operation of the on pump switch to off pump; addition of other surgery such as surgery aneurysmectomy LV; performed endarterctomy on the involved vessels; unwillingness to continuing research, patient died during the study.The number of sample size based on other studies has been determined 50. Before the surgery all of the patients in both groups were inform about the benefits of this research and then if they signed the consent form will continue in the study. Patients were assured that any time they can come out of research.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Glucos. Timepoint: Three time every six hour before surgery and every one hour due to surgery and after surgery in ICU and every six hour after surgery in ward till discharge. Method of measurement: The level of serum. | — |
Secondary
| Measure | Time frame |
|---|---|
| Creatinin. Timepoint: One time befor surgery and three time after surgery. Method of measurement: The level of serum.;Hospitalization days. Timepoint: Until discharge from the hospital. Method of measurement: Observations and patient file.;Health costs. Timepoint: At the end of the study. Method of measurement: Health costs form.;Surgical site infection. Timepoint: Beginning of study on the first, second, third, fourth and fifth after operation. Method of measurement: According fever and purulent discharge from the surgical site. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Rahnavard
Tehran University of Medical Sciences
Outcome results
None listed